Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Cullinan TherapeuticsCGEM | Open-market sale10b5-1 plan | 05/05 | 05/06 | 8,000 sh2 trades | $14.62avg. | $116,996 | −4.6% | |
Jennifer MichaelsonChief Scientific Officer | Cullinan TherapeuticsCGEM | Open-market sale10b5-1 plan | 03/05 | 03/09 | 8,000 sh | $15.68 | $125,440 | −4.5% |
Jennifer MichaelsonChief Scientific Officer | Cullinan TherapeuticsCGEM | Open-market sale10b5-1 plan | 02/25 | 02/26 | 1,780 sh | $14.14 | $25,169.2 | −1.0% |
Nadim AhmedPresident and CEO | Cullinan TherapeuticsCGEM | Open-market sale | 02/24 | 02/25 | 13,515 sh | $14.47 | $195,562.05 | −3.3% |
Cullinan TherapeuticsCGEM | Open-market sale10b5-1 plan | 02/23–02/24 | 02/25 | 5,353 sh2 trades | $14.31avg. | $76,616.95 | −2.9% | |
Jacquelyn L. SumerChief Legal Officer | Cullinan TherapeuticsCGEM | Open-market sale | 02/24 | 02/25 | 3,601 sh | $14.47 | $52,106.47 | −2.7% |
Jeffrey Alan JonesChief Medical Officer | Cullinan TherapeuticsCGEM | Open-market sale | 02/24 | 02/25 | 4,582 sh | $14.47 | $66,301.54 | −2.8% |
Cullinan TherapeuticsCGEM | Open-market sale | 02/20 | 02/23 | 4,398 sh | $13.62 | $59,900.76 | −3.4% | |
Nadim AhmedPresident and CEO | Cullinan TherapeuticsCGEM | Open-market sale | 02/20 | 02/23 | 16,381 sh | $13.62 | $223,109.22 | −3.9% |
Cullinan TherapeuticsCGEM | Open-market sale10b5-1 plan | 02/20 | 02/23 | 11,742 sh2 trades | $14.08avg. | $165,366.04 | −6.1% | |
Jacquelyn L. SumerChief Legal Officer | Cullinan TherapeuticsCGEM | Open-market sale | 02/20 | 02/23 | 3,742 sh | $13.62 | $50,966.04 | −2.8% |
Jeffrey Alan JonesChief Medical Officer | Cullinan TherapeuticsCGEM | Open-market sale | 02/20 | 02/23 | 4,982 sh | $13.62 | $67,854.84 | −2.9% |
Jennifer MichaelsonChief Scientific Officer | Cullinan TherapeuticsCGEM | Open-market sale | 02/12 | 02/13 | 416 sh | $12.03 | $5,004.48 | −0.3% |
Jennifer MichaelsonChief Scientific Officer | Cullinan TherapeuticsCGEM | Open-market sale10b5-1 plan | 01/22 | 01/23 | 4,000 sh | $12.30 | $49,200 | −3.0% |
Nadim AhmedPresident and CEO | Cullinan TherapeuticsCGEM | Open-market sale | 25/12/23 | 25/12/29 | 9,922 sh | $10.01 | $99,319.22 | −2.3% |
Jennifer MichaelsonChief Scientific Officer | Cullinan TherapeuticsCGEM | Open-market sale10b5-1 plan | 25/12/19 | 25/12/22 | 1,345 sh | $10.01 | $13,463.45 | −1.0% |
Jennifer MichaelsonChief Scientific Officer | Cullinan TherapeuticsCGEM | Open-market sale | 25/12/18 | 25/12/19 | 2,898 sh | $9.67 | $28,023.66 | −2.1% |
Jacquelyn L. SumerChief Legal Officer | Cullinan TherapeuticsCGEM | Open-market sale | 25/12/18 | 25/12/19 | 3,480 sh | $9.67 | $33,651.6 | −2.5% |
Jeffrey Alan JonesChief Medical Officer | Cullinan TherapeuticsCGEM | Open-market sale | 25/12/18 | 25/12/19 | 4,632 sh | $9.67 | $44,791.44 | −2.7% |
Cullinan TherapeuticsCGEM | Open-market sale10b5-1 plan | 25/12/12–25/12/15 | 25/12/16 | 3,143 sh2 trades | $12.23avg. | $38,432.74 | −2.2% |